NASDAQ: CDNA · Industrial Applications and Services · 7 alerts · CIK 1217234
Share price
$73.72Close, Nov 16
Market cap
$3.87B
Shares outstanding
52.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CareDx, Inc. filings on SEC EDGAR ↗
CareDx Director Michael Goldberg Sells $1.09M of Stock
Michael Goldberg, Director, sold 13,800 shares of CareDx, Inc. at $78.32 to $79.85 a share (average $79.15) in 3 transactions, worth $1.09M in total on Nov 12, 2026. Shares held after the trade: 48,526 (-4.4%).
CareDx CFO & COO Keith Kennedy Sells $166K of Stock
Keith Kennedy, CFO & COO, sold 2,097 shares of CareDx, Inc. at $78.78 to $79.61 a share (average $79.29) in 2 transactions, worth $166K in total on Nov 12, 2026. Shares held after the trade: 199,147 (-0.6%).
CareDx Secretary and General Counsel Jeffrey Adam Novack Sells $332K of Stock
Jeffrey Adam Novack, Secretary and General Counsel, sold 4,096 shares of CareDx, Inc. at $80.47 to $83.33 a share (average $81.13) in 3 transactions, worth $332K in total on Nov 10, 2026. Shares held after the trade: 96,604 (-0.9%).
CareDx CFO & COO Keith Kennedy Sells $4.82M of Stock
Keith Kennedy, CFO & COO, sold 61,961 shares of CareDx, Inc. at $76.55 to $83.60 a share (average $77.82) in 8 transactions, worth $4.82M in total on Nov 5, 2026. Shares held after the trade: 199,147 (-0.3%).
CareDx reported a significant increase in total revenue to $389.0 million for the nine months ended September 30, 2026, compared to $271.4 million in the prior year. The company achieved a net income of $132.7 million during this period, primarily driven by a $113.0 million gain from the sale of its lab products business and strong growth in testing services revenue.
CareDx reported third quarter 2026 revenue of $139 million, a 39% year-over-year increase driven by strong growth in Testing Services. The company achieved GAAP net income of $19 million and raised its full-year 2026 revenue guidance to a range of $520 million to $530 million.
“We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.”
John Hanna, President and Chief Executive Officer of CareDx
“We see significant clinical interest in how molecular information can inform more decisions across a patient’s care journey, while continuing to make our solutions easier for providers to adopt and patients to access. We believe these dynamics create meaningful opportunities for continued profitable growth.”
John Hanna, President and Chief Executive Officer of CareDx